NCT03776318 - Long-Term Follow-up Safety of Clonidine Micropellets | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

January 22, 2021

Study Completion Date

May 31, 2021

Conditions

Lumbosacral Radiculopathy

Interventions

DRUG

Long-Term Safety Follow-up

STX-015-18-01 long-term safety follow-up

Trial Locations (25)

14618

Sollis Clinical Study Site 31, Rochester

22205

Sollis Clinical Study Site 30, Washington D.C.

26506

Sollis Clinical Study Site 23, Morgantown

27103

Sollis Clinical Study Site 18, Winston-Salem

33135

Sollis Clinical Study Site 38, Miami

33316

Sollis Clinical Study Site 35, Fort Lauderdale

36605

Sollis Clinical Study Site 36, Mobile

41017

Sollis Clinical Study Site 10, Edgewood

44106

Sollis Clinical Study Site 21, Cleveland

44195

Sollis Clinical Study Site 33, Cleveland

53792

Sollis Clinical Study Site 27, Madison

60657

Sollis Clinical Study Site 13, Chicago

61704

Sollis Clinical Study Site 12, Bloomington

66160

Sollis Clinical Study Site 14, Kansas City

66210

Sollis Clinical Study Site 37, Overland Park

73013

Sollis Clinical Study Site 19, Edmond

75240

Sollis Clinical Study Site 42, Dallas

77004

Sollis Clinical Study Site 34, Houston

84107

Sollis Clinical Study Site 47, Salt Lake City

85053

Sollis Clinical Study Site 44, Phoenix

85724

Sollis Clinical Study Site 40, Tucson

92270

Sollis Clinical Study Site 49, Rancho Mirage

97401

Sollis Clinical Study Site 46, Eugene

02445

Sollis Clinical Study Site 15, Brookline

07702

Sollis Clinical Study Site 17, Shrewsbury

All Listed Sponsors

lead

Sollis Therapeutics, Inc.

INDUSTRY